In Slovakia, the anti-obesity drug Ozempic and similar medications are increasingly prescribed by doctors across various specialties, not limited to endocrinology.
In Slovakia, there is a growing trend where medical professionals from various specializations, including child neurologists and dentists, are prescribing anti-obesity medications such as Ozempic and Mounjaro. These drugs, which suppress appetite and promote weight loss, have gained immense popularity, and individuals without diabetes can now access them at their own expense with a doctor's prescription.
The phenomenon has raised concerns among pharmacists and medical professionals, who report that prescriptions for these medications are being issued by doctors whose expertise does not align with obesity or diabetes treatment. For instance, anonymized prescription data reveals instances where Ozempic was prescribed by a pediatric neurologist to a patient born in 1969, indicating a potential mismatch between the prescriber's specialty and the purpose of the medication.
This practice could have various implications for patient safety and the appropriateness of treatment. The influx of prescriptions from unrelated specialties might reflect wider societal trends in weight management and a shift towards the normalization of using medications for weight loss, raising questions about the long-term health impacts and the potential need for specialized oversight in prescription practices for such medications.
